Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

After spinning off from Abbott Labs in 2013, biopharmaceutical giant AbbVie had to establish its own culture. Here's how the ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

AbbVie holds a strong portfolio of marketed and pipeline drugs. While the increasing competition to the company's key drug Humira should slow the growth for the company in the near term, we believe ...

Even more alarming is AbbVie's payout ratio of 216.7%, far surpassing the peer average of 141%. This sky-high figure means ...

AbbVie became a stand-alone company in 2012 after it split from its former parent company, Abbott Laboratories. Since then, it has increased its payouts by an impressive 288%. When including the ...

AbbVie (NYSE: ABBV) has long been a darling of dividend growth investors, and for good reason. Since its spinoff from Abbott Laboratories in 2013, the pharmaceutical titan has been a dividend ...

AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...

Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from ...

AbbVie has succeeded in winning tentative approval to buy the Irish drug maker Shire, and Mylan Laboratories said it would acquire the international generic drug business from Abbott Laboratories.